Could a cystic fibrosis drug help brain bleed survivors walk again?
NCT ID NCT06723717
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving dornase alfa (a drug already used for cystic fibrosis) daily for up to 14 days after a brain bleed from a ruptured aneurysm can help people recover better. The goal is to see if more patients can live independently at 6 months. The trial will enroll 304 adults and compares the drug to standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dornase alfa (Pulmozyme®)
What this could lead to
If it works, this could offer a new treatment to prevent delayed brain damage after a ruptured aneurysm, helping more survivors regain independence.
What could go wrong
This is a Phase 2 trial with 304 participants, so results are still early. The drug has not been proven for this condition, and there is no guarantee it will improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DELAYED CEREBRAL ISCHEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
CHU Poitiers
RECRUITINGPoitiers, Poitiers, 86000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU Strasbourg
RECRUITINGStrasbourg, Strasbourg, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Grenoble
RECRUITINGGrenoble, Grenoble, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
CHU de Montpellier
RECRUITINGMontpellier, Montpellier, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
HCL de Lyon
RECRUITINGLyon, Lyon, 69002, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hôpital FOCH
RECRUITINGSuresnes, Île-de-France Region, France
Contact Phone: •••-•••-•••• Email: •••••@•••••